drugset / Trial / NCT00646932
Paricalcitol Injection Phase II Trial
Non-randomizedParallel-groupOpen-label
Summary
The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure.
Timeline
- Start
- 2005-11
- Primary completion
- 2007-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paricalcitol | Other / unclassified | 0.04 ug/kg | Intravenous |
| Subject | Paricalcitol | Other / unclassified | 0.08 ug/kg | Intravenous |
| Subject | Paricalcitol | Other / unclassified | 0.16 ug/kg | Intravenous |
| Subject | Paricalcitol | Other / unclassified | 0.24 ug/kg | Intravenous |